KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) EBT (2017 - 2025)

Historic EBT for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to -$187.0 million.

  • Moderna's EBT fell 99047.62% to -$187.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 billion, marking a year-over-year decrease of 3399.92%. This contributed to the annual value of -$3.6 billion for FY2024, which is 849.82% up from last year.
  • Per Moderna's latest filing, its EBT stood at -$187.0 million for Q3 2025, which was down 99047.62% from -$818.0 million recorded in Q2 2025.
  • Moderna's 5-year EBT high stood at $5.4 billion for Q4 2021, and its period low was -$2.0 billion during Q3 2023.
  • For the 5-year period, Moderna's EBT averaged around $702.2 million, with its median value being $21.0 million (2024).
  • Its EBT has fluctuated over the past 5 years, first soared by 271794.87% in 2021, then crashed by 179142.86% in 2024.
  • Over the past 5 years, Moderna's EBT (Quarter) stood at $5.4 billion in 2021, then tumbled by 69.41% to $1.7 billion in 2022, then tumbled by 95.77% to $70.0 million in 2023, then crashed by 1791.43% to -$1.2 billion in 2024, then skyrocketed by 84.21% to -$187.0 million in 2025.
  • Its EBT was -$187.0 million in Q3 2025, compared to -$818.0 million in Q2 2025 and -$964.0 million in Q1 2025.